I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Sally Crawford Biography and Net Worth

Director of Insulet

Ms. Crawford has served on our Board of Directors since 2008 and served as our Lead Independent Director from May 2009 to May 2013. She served as Chief Operating Officer of Healthsource, Inc., a publicly-held managed care organization from its founding in 1985 until 1997. During her tenure at Healthsource, she led the development of its operating systems and marketing strategies and supported strategic alliances with physicians, hospitals, insurers and other healthcare companies. Since 1997, Ms. Crawford has been a healthcare consultant. She serves on the Board of Directors of Hologic, Inc. and Prolacta Bioscience Inc. and Abcam plc. She also served on the Board of Directors of Exact Sciences Corporation from 1999 to 2015, Zalicus Inc. from 2007 to 2014, Universal American from 2008 to 2017, Chittenden Corporation from 1998 to 2008, and Cytyc Corporation (which merged with Hologic, Inc. in October 2007) from 1998 to 2007. Ms. Crawford earned a Bachelor of Arts from Smith College and a Master of Science from Boston University. She brings experience as a board and committee member of public companies, a detailed understanding of the healthcare and managed care industries, which are directly relevant to our business, and the practical knowledge gained in her previous role as chief operating officer of a publicly-held managed care organization.

What is Sally Crawford's net worth?: The estimated net worth of Sally Crawford is at least $10.55 million as of March 13th, 2023. Ms. Crawford owns 40,127 shares of Insulet stock worth more than $10,550,592 as of November 23rd. This net worth evaluation does not reflect any other assets that Ms. Crawford may own. Learn More about Sally Crawford's net worth.
How do I contact Sally Crawford?: The corporate mailing address for Ms. Crawford and other Insulet executives is 100 NAGOG PARK, ACTON MA, 01720. Insulet can also be reached via phone at (978) 600-7000 and via email at [email protected]. Learn More on Sally Crawford's contact information.
Has Sally Crawford been buying or selling shares of Insulet?: Sally Crawford has not been actively trading shares of Insulet over the course of the past ninety days. Most recently, Sally Crawford sold 10,000 shares of the business's stock in a transaction on Friday, June 4th. The shares were sold at an average price of $269.07, for a transaction totalling $2,690,700.00. Following the completion of the sale, the director now directly owns 20,306 shares of the company's stock, valued at $5,463,735.42. Learn More on Sally Crawford's trading history.
Who are Insulet's active insiders?: Insulet's insider roster includes Charles Alpuche (COO), Eric Benjamin (SVP), Luciana Borio (Director), Bret Christensen (EVP), Sally Crawford (Director), John Fallon (Director), Mark Field (SVP and Chief Technology Officer), James Hollingshead (CEO), Dan Manea (SVP), Wayde McMillan (CFO), Shacey Petrovic (CEO), Timothy Scannell (Director), Prem Singh (SVP), and Michael Spears (SVP). Learn More on Insulet's active insiders.
Are insiders buying or selling shares of Insulet?: In the last twelve months, insiders at the medical instruments supplier sold shares 5 times. They sold a total of 25,540 shares worth more than $4,527,624.61. The most recent insider tranaction occured on June, 14th when SVP Mark N Field sold 1,500 shares worth more than $299,940.00. Insiders at Insulet own 0.5% of the company. Learn More about insider trades at Insulet.
Information on this page was last updated on 6/14/2024.

Sally Crawford Insider Trading History at Insulet

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/4/2021	Sell	10,000	$269.07	$2,690,700.00	20,306
5/31/2019	Sell	28,347	$108.60	$3,078,484.20	28,469
8/29/2013	Sell	9,000	$33.42	$300,780.00	7,000
6/14/2013	Sell	31,000	$30.47	$944,570.00

Sally Crawford Buying and Selling Activity at Insulet

Insulet Company Overview

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Today's Range

Now: $262.93

$259.63

$264.57

50 Day Range

MA: $241.32

$227.79

$275.70

2 Week Range

Now: $262.93

$160.19

$279.40

Volume

457,888 shs

Average Volume

775,800 shs

Market Capitalization

$18.44 billion

P/E Ratio

45.02

Dividend Yield

N/A

Beta

1.22

I was wrong. Dead wrong.

From Porter & Company | Ad